Camber Capital Management’s GSK GSK Stock Holding History

Camber Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,500,000	Closed	-$91.5M	–	34
2024 Q4	$84.5M	Sell	2,500,000 -500,000	-17%	-$18M	1.96%	16
2024 Q3	$123M	Buy	3,000,000 +325,000	+12%	+$13.3M	3.9%	9
2024 Q2	$103M	Buy	2,675,000 +500,000	+23%	+$21M	2.85%	13
2024 Q1	$93.2M	Hold	2,175,000	–	–	2.29%	15
2023 Q4	$80.6M	Sell	2,175,000 -675,000	-24%	-$24.2M	2.05%	15
2023 Q3	$103M	Sell	2,850,000 -1,250,000	-30%	-$44.4M	3.41%	12
2023 Q2	$146M	Sell	4,100,000 -500,000	-11%	-$17.9M	4.76%	8
2023 Q1	$164M	Buy	4,600,000 +850,000	+23%	+$29.7M	5.03%	7
2022 Q4	$132M	Buy	3,750,000 +1,250,000	+50%	+$41.6M	4.52%	8
2022 Q3	$73.6M	Buy	+2,500,000	New	+$94.8M	2.25%	17
2022 Q2	–	Sell	-800,000	Closed	-$43.6M	–	42
2022 Q1	$43.6M	Sell	800,000 -1,200,000	-60%	-$65.2M	1.58%	22
2021 Q4	$110M	Sell	2,000,000 -200,000	-9%	-$10.4M	3.79%	9
2021 Q3	$105M	Hold	2,200,000	–	–	3.24%	12
2021 Q2	$110M	Buy	2,200,000 +200,000	+10%	+$9.61M	3.69%	12
2021 Q1	$89.2M	Sell	2,000,000 -800,000	-29%	-$36.3M	3.06%	12
2020 Q4	$129M	Buy	2,800,000 +2,440,000	+678%	+$112M	4.52%	9
2020 Q3	$16.9M	Sell	360,000 -2,040,000	-85%	-$102M	0.89%	28
2020 Q2	$122M	Hold	2,400,000	–	–	7%	6
2020 Q1	$114M	Buy	+2,400,000	New	+$128M	6.79%	4
2019 Q4	–	Sell	-400,000	Closed	-$21.3M	–	33
2019 Q3	$21.3M	Hold	400,000	–	–	1.12%	28
2019 Q2	$20M	Buy	+400,000	New	+$20.1M	0.93%	26
2019 Q1	–	Sell	-1,600,000	Closed	-$76.4M	–	33
2018 Q4	$76.4M	Buy	+1,600,000	New	+$78.8M	3.63%	10
2018 Q2	–	Sell	-1,200,000	Closed	-$58.6M	–	36
2018 Q1	$58.6M	Hold	1,200,000	–	–	2.88%	15
2017 Q4	$53.2M	Buy	+1,200,000	New	+$55.4M	2.6%	14
2015 Q1	–	Sell	-1,400,000	Closed	-$74.8M	–	40
2014 Q4	$74.8M	Buy	1,400,000 +440,000	+46%	+$24.6M	4.97%	4
2014 Q3	$55.2M	Buy	+960,000	New	+$58.9M	5.18%	5

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Camber Capital Management's GSK Position: Q1 2025 in Review

Camber Capital Management sold out of GSK (GSK) in Q1 2025, closing a stake of 2,500,000 shares — an estimated $91.5M sold.

Camber Capital Management first reported a position in GSK in Q3 2014 and held it in 26 quarters. The position peaked at $164M in Q1 2023. 858 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Camber Capital Management reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Camber Capital Management sold 2,500,000 GSK shares in Q1 2025, an estimated $91.5M.
Camber Capital Management first reported a position in GSK in Q3 2014 and held it in 26 quarters.
Camber Capital Management's GSK position peaked at $164M in Q1 2023.
858 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Camber Capital Management's 13F filing for Q1 2025, filed 15 May 2025.